Loading…
Grace Therapeutics, Inc. is projected to rise to $2.81 by 2027, a +15% move from its current price of $2.45. GRCE is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $2.38 | $2.45 | $2.52 | +0.06% |
| Jul 13 | $2.35 | $2.45 | $2.56 | +0.11% |
| Jul 14 | $2.33 | $2.45 | $2.58 | +0.17% |
| Jul 15 | $2.32 | $2.46 | $2.60 | +0.23% |
| Jul 16 | $2.30 | $2.46 | $2.62 | +0.28% |
| Jul 17 | $2.29 | $2.46 | $2.64 | +0.34% |
| Jul 18 | $2.28 | $2.46 | $2.66 | +0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.28 | $2.46 | $2.66 | +0.40% |
| Week 2 | $2.21 | $2.47 | $2.75 | +0.79% |
| Week 3 | $2.17 | $2.48 | $2.83 | +1.19% |
| Week 4 | $2.13 | $2.49 | $2.90 | +1.59% |
| Week 5 | $2.10 | $2.50 | $2.97 | +1.99% |
| Week 6 | $2.08 | $2.51 | $3.03 | +2.40% |
| Week 7 | $2.05 | $2.52 | $3.09 | +2.80% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Grace Therapeutics, Inc. is a healthcare company focused on the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. Its lead product candidate is GTX-104, an intravenous infusion to treat subarachnoid hemorrhage.
It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN).
The company was formerly known as Acasti Pharma Inc and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Grace Therapeutics, Inc. (GRCE) is categorized in Healthcare. Its current price is $2.38 and its market capitalization is $36.83M, with a rank of 4717.
The forecast for 2026–2050 envisions meaningful upside. The 2026 average price is $2.38, rising through decades to a 2050 average of $25.16, with a 2030 average of $4.42 and a 2040 average of $11.41. ROI figures rise from 0 in 2026 to 85.6 in 2030, 379.4 in 2040, and 957.2 in 2050. Sentiment shifts from Neutral in 2026–2027 to Bullish from 2028 onward.
A major floor 20.1% below — a decisive break under it would weaken the trend.
The nearest floor, 10.2% below — buyers have tended to step in here.
The nearest ceiling, 9.8% above — a clean break opens room to run.
A major ceiling 109.4% above — clearing it would confirm fresh momentum.
Key GRCE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GRCE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.48 | Sell | $2.45 | Buy |
| MA 10 | $2.40 | Buy | $2.42 | Buy |
| MA 20 | $2.34 | Buy | $2.39 | Buy |
| MA 50 | $2.33 | Buy | $2.55 | Sell |
| MA 100 | $3.19 | Sell | $2.86 | Sell |
| MA 200 | $3.25 | Sell | $3.07 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.86 | Neutral |
| Stoch RSI (14) | 68.74 | Neutral |
| CCI (20) | 81.06 | Neutral |
| Williams %R (14) | -27.59 | Info |
| MACD (12,26,9) | 0.03 | Buy |
| ROC (12) | 2.51 | Buy |
| Bollinger %B (20,2) | 0.76 | Neutral |
| Stochastic %K (14) | 72.41 | Neutral |
| TRIX (15) | -0.09 | Sell |
| Awesome (5,34) | 0.12 | Buy |
| Ultimate (7,14,28) | 62.88 | Neutral |
| Momentum (10) | 0.08 | Buy |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 2.51 | Sell |
| ADX (14) | 12.21 | Neutral |
| ATR (14) | 0.06 | Info |
Near-term technical picture shows a bullish tilt in sentiment. RSI14 is 40, with a 50-day moving average near $2.71 and a 200-day moving average near $3.30.
The stock trades with a support level at $2.15 and a resistance at $2.69. The 30-day price range spans from $1.96 to $2.89, indicating a broad swing around the current level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.10 | $2.45 | $3.44 | 0% | Neutral | |
| $2.22 | $2.81 | $3.76 | +15% | Neutral | |
| $2.62 | $3.41 | $4.76 | +39% | Bullish | |
| $2.77 | $3.70 | $5.32 | +51% | Bullish | |
| $3.33 | $4.55 | $6.72 | +86% | Bullish | |
| $4.18 | $5.83 | $8.79 | +138% | Bullish | |
| $4.27 | $6.07 | $9.33 | +148% | Bullish | |
| $4.67 | $6.74 | $10.57 | +175% | Bullish | |
| $4.89 | $7.18 | $11.44 | +193% | Bullish | |
| $4.63 | $6.92 | $11.20 | +182% | Bullish | |
| $7.65 | $12.30 | $21.23 | +402% | Bullish | |
| $15.03 | $27.43 | $52.02 | +10.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.10 | $2.45 | $3.03 | +0.00% |
| August 2026 | $2.19 | $2.59 | $3.14 | +5.56% |
| September 2026 | $2.16 | $2.58 | $3.17 | -0.27% |
| October 2026 | $2.23 | $2.68 | $3.33 | +3.76% |
| November 2026 | $2.30 | $2.77 | $3.47 | +3.48% |
| December 2026 | $2.25 | $2.73 | $3.44 | -1.56% |
Click any year to see its month-by-month GRCE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, GRCE could reach as high as $3.44, with a base case around $2.45 and support toward $2.10 — roughly 0% from $2.45. Price action looks broadly range-bound.
Expect GRCE to range from $2.22 to $3.76 through 2027. The $2.81 average target implies a +15% move from current prices. That is up +15% on the projected 2026 average. A consolidation phase looks the most probable path here.
The GRCE price prediction for 2028 points to an average of $3.41 (low $2.62, high $4.76) — a potential gain of +39% on today's $2.45. Momentum favours further upside here.
In 2029, GRCE is projected to trade between $2.77 and $5.32, averaging $3.70 — a potential gain of +51% from today's $2.45. That is up +9% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Grace Therapeutics, Inc.'s 2030 outlook centres on $4.55, within a $3.33 to $6.72 range. That is up +23% on the projected 2029 average. That marks a +86% change versus current levels. Momentum favours further upside here.
By 2031, GRCE could reach as high as $8.79, with a base case around $5.83 and support toward $4.18 — roughly +138% from $2.45. Buyers look set to stay in control over this stretch.
Expect GRCE to range from $4.27 to $9.33 through 2032. The $6.07 average target implies a +148% move from current prices. That is up +4% on the projected 2031 average. Momentum favours further upside here.
The GRCE price prediction for 2033 points to an average of $6.74 (low $4.67, high $10.57) — a potential gain of +175% on today's $2.45. Buyers look set to stay in control over this stretch.
In 2034, GRCE is projected to trade between $4.89 and $11.44, averaging $7.18 — a potential gain of +193% from today's $2.45. That is up +6% on the projected 2033 average. Momentum favours further upside here.
Grace Therapeutics, Inc.'s 2035 outlook centres on $6.92, within a $4.63 to $11.20 range. That is -4% versus the projected 2034 average. That marks a +182% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, GRCE could reach as high as $21.23, with a base case around $12.30 and support toward $7.65 — roughly +402% from $2.45. Momentum favours further upside here.
Expect GRCE to range from $15.03 to $52.02 through 2050. The $27.43 average target implies a +10.2x move from current prices. That is up +123% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in GRCE today (≈ 408.163265 GRCE) could be worth
$11,196.41
+$10,196.41 (+1020%) by 2050 · US Dollar
Based on the average projected GRCE price of $27.43 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GRCEwould be worth at today's price.
$1,000 invested in GRCE on Jul 10, 2025 (≈ 322.580655 GRCE) would be worth
$790.32
-$209.68 (-21.0%) today · 0.79× · US Dollar
Based on a GRCE entry price of $3.1 vs. today's $2.45.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.37 | $1,033.76 | +3.4% |
| 1 month ago | $2.31 | $1,060.61 | +6.1% |
| 3 months ago | $3.59 | $682.45 | -31.8% |
| 6 months ago | $3.6 | $680.56 | -31.9% |
| 1 year ago | $3.1 | $790.32 | -21.0% |
| All time (5.0y) ago | $26.4 | $92.8 | -90.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GRCE forecast.
Our base-case forecast reaches $4.90 around 2031.
Implied market cap at $4.90: $79.74M
The multi-year forecast points to substantial upside, with Neutral sentiment in 2026 and 2027 and Bullish sentiment from 2028 onward. By 2030, the average price is forecast at $4.42 with an ROI of 85.6; by 2040 the average is $11.41 with an ROI of 379.4; by 2050 the average is $25.16 with an ROI of 957.2.
From 2028 onward, the forecasted averages rise into the high single digits and beyond, with 2031–2035 showing continued Bullish sentiment and higher average prices (e.g., 2031 $5.53, 2032 $5.74, 2033 $6.48, 2034 $6.66, 2035 $6.39). These estimates reflect upside potential but are not guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $4.42, a min of $3.22, a max of $6.54, and an ROI of 85.6 with a Bullish outlook.
The forecast shows a path of rising averages and Bullish sentiment from 2028 onward, with ROI progressing from 16.8 in 2027 to 957.2 by 2050, though these are estimates, not guarantees.
Yes. The 2040 forecast shows an average price of $11.41, indicating the possibility of surpassing $10 by that timeframe, with prior years showing smaller but growing averages.
Current price is $2.38 and market cap is $36.83M.
The 30-day range is from $1.96 to $2.89.
Grace Therapeutics, Inc. Community Discussion
0Share your Grace Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.